Scholars@Duke
Nrupen Bhavsar

Nrupen Bhavsar

Associate Professor in Surgery
Surgery, Surgical Sciences
nrupen.bhavsar@duke.edu
710 W. Main St, Durham, NC 27701
710 W. Main St, Durham, NC 27710

Scholarly Works - Conferences

Association of baseline quality of life (QOL) and early death in patients with metastatic renal cell carcinoma (mRCC) in the real-world prospective observational ODYSSEY study.

Conference Journal of Clinical Oncology · June 1, 2026 4559Background: Baseline QOL has been linked to survival in mRCC therapy clinical tri ... Full text Cite

C22-21 Social Drivers of Health and Post-critical Illness Depression

Conference American Journal of Respiratory and Critical Care Medicine · May 1, 2026 AbstractIntroductionOne in three survivors of critical illness experience depression. We know that clinical factors such as sev ... Full text Cite

Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.

Conference Journal of Clinical Oncology · March 1, 2026 Lack of standardized reporting and collection of patient-reported outcomes (PROs) limits cross-trial comparisons of first-line IO-based regimens for mRCC. Prospectively collected real world data may fill this important knowledge gap. Pts with stable/improv ... Full text Cite

Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.

Conference Journal of Clinical Oncology · June 2025 4553Background: AS is a recognized strategy in select pts with mRCC to maximize QOL and delay potential toxicity of systemic ... Full text Cite

Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study.

Conference Journal of Clinical Oncology · June 2025 4558Background: In the past 7 years, 4 immuno-oncology (IO) based combinations have been approved for mRCC. However, QOL data ... Full text Cite

Role of Built and Social Environments in Post-COVID Recovery: A Qualitative Study of Patients and Caregivers

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · May 1, 2024 Link to item Cite

Preliminary analysis of baseline characteristics, patient reported outcomes (PROs), and treatment selection in ODYSSEY

Conference Journal of Clinical Oncology · January 1, 2024 Background: Tyrosine kinase inhibitors (TKI) and immuno-oncology (IO) agents alone or in combination have revolutionized the landscape of management for untreated metastatic renal cell carcinoma (mRCC). Baseline quality of life (QOL) outside of interventio ... Full text Cite

Social Determinants of Health Data Capture Within National and Health System Data Sources

Conference Journal of the American College of Surgeons · November 2022 Full text Cite

Abstract P112: Impact Of Look Back Period Length On Associations When Using Electronic Health Record Data For Epidemiologic Research

Conference Circulation · May 25, 2021 Introduction: Studies using electronic health record (EHR) data often have a limited number of years available for analysis. There is a trade off between the look back period length used to define bas ... Full text Cite

1016 Multiple Sleep Disturbances and Hypertension Risk Among White, Black, and Hispanic/Latina Women

Conference Sleep · May 27, 2020 AbstractIntroductionPoor sleep has been associated with a higher risk of hypertension, but few prospective studies have included multi ... Full text Cite

Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab

Conference Cancer Research · February 15, 2016 AbstractBackground: Baseline TIL density and T-cell clonality predict pathological complete response (pCR) to neoadjuvant (NA) trastuzumab (TRAS). Preclinical data suggests that a major mechanism of TRAS is ... Full text Cite

Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.

Conference Journal of Clinical Oncology · January 10, 2016 563 Background: Clinical trials mRCC pts are different from real world pts, resulting in bias in the literature. The MaRCC Registry is designed to survey questions not asked in tri als, such as why physicians make certain managem ... Full text Cite

Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.

Conference Journal of Clinical Oncology · January 10, 2016 617 Background: Over the past decade, seven agents were approved for metastatic renal cell carcinoma (mRCC) leading to a rapidly evolving clinical landscape. Clinical trials addressing treatment efficacy, sequencing, and other qu ... Full text Cite

Radiosurgery for Brain Metastases in Melanoma Patients Receiving Ipilimumab

Conference International Journal of Radiation Oncology*Biology*Physics · November 2015 Full text Cite

The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343.

Conference Cancer · January 15, 2015 BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 randomized phase 3 trial established lumpectomy and adjuvant therapy with tamoxifen alone, rather than both radiotherapy and tamoxifen, as a reasonable treatment course for women aged >70 years with ... Full text Link to item Cite